JNJ vs PFE: six-factor score, head to head
How Johnson & Johnson and Pfizer Inc.compare on Tapeline’s published six-factor composite score. Descriptive only — a rules-based reading of each name, not a recommendation.
Today, JNJ scores 66 and PFE scores 63on Tapeline’s six-factor composite. JNJ carries the higher composite score today. Here’s how the six factors line up.
| Factor | JNJ | PFE |
|---|---|---|
| Trend | 86 | 78 |
| Relative Strength | 69 | 46 |
| Fundamentals | 80 | 58 |
| Smart Money | 32 | 88 |
| Macro | 50 | 50 |
| Momentum | 67 | 52 |
trend among this ticker's highest-scoring factors — fundamentals factor in the top band (revenue, margin, ROE inputs), while relative-strength factor on the upper side vs the sector.
smart-money factor above the score midpoint; positive trend factor reading.
The Tapeline Score is a descriptive, rules-based measure for information only — not investment advice or a recommendation to buy or sell. See the six-factor method and the public scorecard.
More comparisons
FAQ
- How do JNJ and PFE compare on Tapeline?
- Tapeline scores JNJ 66/100 and PFE 63/100 on its published six-factor composite score (trend, relative strength, fundamentals, smart money, macro, momentum). The page breaks the two scores down factor by factor.
- Which has the higher Tapeline score, JNJ or PFE?
- JNJ has the higher composite score today (66 vs 63). The score is a descriptive measure, not a recommendation — see the per-factor breakdown above.
- Is this investment advice?
- No. Tapeline publishes a descriptive, rules-based six-factor score for information only. It is not a recommendation to buy or sell, and every top pick is back-checked publicly at /scorecard.